Curated News
By: NewsRamp Editorial Staff
July 23, 2026

Lantern Pharma Secures Key Patent for AI-Guided Cancer Therapy LP-184

Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Lantern Pharma's patent for LP-184 biomarker gives edge in precision oncology, targeting ovarian, liver, kidney, and thyroid cancers.
  • Lantern's RADR AI identified a three-gene biomarker (PTGR1, PTPN14, ASPH) to select patients for LP-184 therapy, with 45% disease control rate.
  • LP-184's precision targeting could improve outcomes for cancer patients by matching therapy to genetic markers, reducing ineffective treatments.
  • Lantern's RADR AI and LP-184 show how artificial intelligence can discover biomarkers for personalized cancer treatment.

Impact - Why it Matters

This news matters because it marks a step toward more personalized cancer treatment, potentially improving outcomes for patients with ovarian, liver, kidney, and thyroid cancers by using a biomarker signature to identify those most likely to benefit from LP-184. The patent also validates Lantern's AI platform, which could accelerate development of targeted therapies and reduce trial failures, offering hope for more effective and less toxic treatments.

Summary

Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the U.S. Patent and Trademark Office issuing a Notice of Allowance for a patent covering methods to select and treat patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The patent is based on a three-gene biomarker signature comprising elevated expression of PTGR1, PTPN14, and ASPH, which helps identify patients likely to benefit from treatment. This precision medicine approach was developed using Lantern's proprietary RADR(R) artificial intelligence platform, which analyzed vast datasets to pinpoint the biomarker signature. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial. Lantern plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while expanding its intellectual property portfolio.

Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its RADR(R) platform to transform cancer therapy development. Its clinical pipeline includes LP-184, LP-284 (targeting hematologic and solid tumors), and LP-300 (evaluated in the HARMONIC Phase 2 trial for never-smoker lung adenocarcinoma). LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's CNS-focused subsidiary. Additionally, Lantern has launched withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research tool for the global biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

This development underscores Lantern's commitment to precision oncology and AI-driven drug development. The biomarker-based patent strengthens the company's position in targeted cancer therapy, potentially improving treatment outcomes by matching patients with the right drug. For more details, visit the full press release at https://ibn.fm/LRGUo.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Secures Key Patent for AI-Guided Cancer Therapy LP-184

blockchain registration record for this content.